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Summary
Objective: The prevalence of osteoarthritis (OA) increases dramatically in women after the age of 50. Animal models are used to study the
effects of hormone depletion [by ovariectomy (OVX)] and estrogen treatment on OA. This review summarizes these animal studies, in order
to get a better insight in the role of hormones on OA.
Method: The literature was systematically reviewed until May 2007. The results were divided into two parts: the effect of OVX on cartilage, and
the effect of estrogen treatment on cartilage. Only studies with an appropriate control group (e.g., sham-operated) were included.
Results and discussion: Eleven out of 16 animal studies showed that OVX resulted in cartilage damage. When only studies using sexually
mature animals were included, we saw that 11 out of 14 studies showed a detrimental effect, indicating considerable evidence for a relation
between cartilage degeneration and OVX in mature animals. The effect of estrogen treatment was inconclusive with only 11 out of 22 animal
studies reporting a beneﬁcial effect on cartilage, whereas all six studies administering selective estrogen receptor modulators (SERMs) after
OVX described protective effects. The discrepancy between the studies may be caused by the large variation in experimental set-up. We sug-
gested a list of quality criteria for animal models since standardisation of design and outcome parameters of animal experiments may help to
compare different studies and to gain better insight in the role of hormones in the osteoarthritic process.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative joint disease, which
results in structural changes in joint tissues, such as articu-
lar cartilage, subchondral bone and synovium. It can lead to
a complete loss of articular surface as well as exposure of
subchondral bone.
From epidemiological studies it is known that before the
age of 50 the prevalence of OA is higher in men1, but after
the age of 50, the prevalence is higher in women2. The prev-
alence increases with age in both women and men, but in
women, the prevalence of OA increases dramatically around
the age of 501,3,4. This coincides with the start of meno-
pause. Taken together, this suggests a link between OA
and ovarian function, and suggests an OA-protective effect
of estrogen. Estrogen receptors alpha and beta, through
which estrogen signals, have been found in several tissues
of the joint, including cartilage, bone, ligaments, and syno-
vium5e9. This indicates that these tissues are responsive*Address correspondence and reprint requests to: Dr Gerjo van
Osch, Department of Orthopaedics, Erasmus MC, University
Medical Center, Room Ee16.14, ’s Gravendijkwal 230, 3015 CE
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533to estrogens. However, estrogen replacement therapy
(ERT) showed contradictory effects on OA10,11.
Besides clinical studies, several animal models are being
used to elucidate the role of estrogens in OA. Ovariectomy
(OVX) is an established procedure to simulate the hormonal
condition of postmenopausal women. It is often used as an
osteoporosis model, but the osteoarthritic changes after
OVX have been investigated as well. The role of estrogen
is also studied by administrating estrogen or an estrogen
antagonist to animals, with or without OVX. In this review
we summarize animal studies investigating a role for OVX
or estrogen treatment in the development of OA, in order
to get a better insight in the pathogenesis of OA. Although
all the tissues in the joint may be involved in the osteoar-
thritic process, we focus on articular cartilage in this review.Methods
Relevant publications were searched in the PubMed database until May
2007. The following keywords were used: [(postmenopaus* OR post-meno-
paus* OR menopause OR OVX OR ovariectomy OR estradiol OR estrogen*
OR female hormon* OR estrogen depletion) AND (osteoarthritis OR OA OR
arthrosis OR osteoarthrosis OR degenerative joint disease OR cartilage)].
Additionally, reference lists of included articles were screened.
A study was eligible for inclusion if all of the following criteria were met: (1)
original data from an own animal study, (2) articular cartilage was studied
(excluding temporomandibular joint, intervertebral discs or growth plate)
and (3) the article was written in English, German or Dutch.
534 Y. H. Sniekers et al.: Effect of OVX and E2 in OA animal modelsWe will summarize the studies in two parts: ﬁrstly, results showing the ef-
fect of OVX on the cartilage, and secondly, results showing the effect of treat-
ment with estrogen or estrogen-antagonists on the cartilage. To study the
effect of estrogen depletion by OVX, it is important to compare the data of
OVX animals to those from Sham-operated or non-operated control animals.
Unfortunately, not all experimental set-ups included such a control group, for
instance when the authors were only interested in the administration of estro-
gen or estrogen-antagonists after OVX. Only studies with a sham-operated or
non-operated control group were included when discussing the effect of OVX.
Study characteristics for study population, treatment, and outcome measures
were extracted as well as the direction of effect reported in the study.Results
A total of 436 articles were identiﬁed initially. Of these, 22
met our selection criteria. After screening the reference lists
of the selected studies and of review articles, another nine
studies were included, bringing the total number of included
studies to 31.
The animals that were used in the selected studies in-
clude mice, rats, rabbits, miniature pigs, sheep, and cyno-
molgus monkeys (Tables IeIII). Most studies investigated
changes in the knee joint, but the parameters studied and
the experimental set-up varied widely.OVX EFFECTSixteen animal studies describing the effect of OVX were
included. These studies are summarized in Table I.
Detrimental effect. Eleven studies found an effect of OVX
on the mechanical properties of the cartilage, its composi-
tion, or cartilage damage, like ﬁbrillation or erosion of the
cartilage surface to complete loss of cartilage.
The mechanical properties of the cartilage after OVX were
tested in a sheep model by Turner et al.12. They found that
theOVX animals had a lower aggregate modulus (ameasure
of compressive stiffness) and a lower shear modulus than
the Sham-animals. According to Turner et al.12, this indicates
a worsening of the mechanical properties. In contrast, an
increase in stiffness was reported in two other studies. An in-
crease in dynamic stiffness, a reduction in phase lag (reﬂect-
ing a change in viscoelastic behaviour consistent with
greater elasticity and reduced dissipation of shear forces),
and locally an increase in shear modulus were described,
again in anOVX sheepmodel13. An increase in cartilage stiff-
ness was also seen in young OVX rabbits, along with an in-
crease in thickness14. In that article it is discussed that the
meaning of these changes in stiffness remains to be eluci-
dated, and could be either beneﬁcial or detrimental.
Apart from biomechanical measurements, compositional
and histological changes were also studied in an OVX sheep
model13. They observed thinning of the femoro-tibial carti-
lage, increased neovascularisation of the calciﬁed cartilage
layer, andhigher histopathological scores, indicating adistur-
bance in the content and/or structural organization of the pro-
teoglycan and collagen macromolecular assembly.
Changes in matrix composition were also studied in the
wrists of miniature pigs after OVX15. The cartilage con-
tained more heavy sulphated glycosaminoglycans (GAG)
(similar as seen with aging) in the OVX animals than in
the control animals. The collagen content was affected as
well. In the OVX animals, type II collagen staining was neg-
ative to weak while in the non-operated controls this was in-
termediate to strong.
The degradation of collagen type II can be studied
by measuring the urinary CTX-II levels. OVX caused anincrease in urinary CTX-II levels in rats, combined with
increased surface erosion16e18. The cartilage damage on his-
tology also increased after OVX in a sheep model19 and in
a guinea pig model20. A similar effect on cartilage damage
was observed in rabbits after OVX combined with corticoste-
roids (to induce osteoporosis)21. OVX increased osteoarthritic
abnormalities in non-operated knees, and also intensiﬁed the
osteoarthritic features in the kneeswhereOAhadbeen exper-
imentally induced by anterior cruciate ligament transection
(ACLT)21. This was also seen in a sheep model in which
OVX was combined with lateral meniscectomy, where OVX
decreased the proteoglycan content even more than after lat-
eral meniscectomy alone19. In another model for surgically
induced OA, namely destabilisation of the medial meniscus
in mice, OVX increased the OA lesions as well22.
No effect. Four of the included studies reported no effect of
OVX on cartilage. OVX did not alter the OA severity score23
or incidence24 in mice. The hormone status [OVX or
orchiectomy (ORX)] also did not appear to inﬂuence the devel-
opment of OA or the distribution of cleaved aggrecans (neo-
peptides) in STR/ort mice25, which have a high incidence of
spontaneous OA. Some of these studies were performed
with very young, sexually immature animals (Table I). In rab-
bits, OVX had no effects on GAG and collagen content in
knee cartilage26, although this study only looked at short
term effects.
Beneficial effect. One study reported a beneﬁcial effect of
OVX on OA. OVX decreased the incidence of OA in mice,
but only if it was performed at 6 months of age27. No signif-
icant effect was seen if mice were ovariectomized at 1 or 12
months of age24,27.ESTROGEN TREATMENT EFFECTIn 22 studies, animalswere treatedwith estrogen (Table II).
In six studies, selective estrogen receptor modulators
(SERMs) were administered (Table III).Estrogen
Beneficial effect. Eleven out of 22 studies reported a bene-
ﬁcial effect of estrogen treatment on OA. Both in male (non-
operated or castrated) and in female mice the incidence of
spontaneous OA was reduced after estradiol treat-
ment28e30. The detrimental effects of OVX on the mechan-
ical properties of cartilage were ameliorated by implantation
of an estradiol pellet in ovariectomized sheep12. The
changes in cartilage stiffness and thickness observed in
rabbits after OVX returned to control levels when estradiol
was administered14. Estradiol also inhibited the changes
in CTX-II excretion and cartilage erosion in rats induced
by OVX16,17. The time of initiation was reported to be impor-
tant, since delayed estrogen therapy was less effective in
this model18. Ham et al.31 reported that long-term (3 years)
estrogen treatment signiﬁcantly reduced the severity of OA
lesions in OVX cynomolgus monkeys. In the same animal
model, ERT increased proteoglycan synthesis by articular
chondrocytes32. The loss of proteoglycans seen after com-
bined OVX and meniscectomy was mitigated by estrogen
treatment in sheep19.
No effect. Three studies reported no effect of estrogen
treatment. Collagen and proteoglycan content were not
Table I
Description of the studies for OVX effect
Study Animal (strain) Treatment Age Number Follow-up Joint Measurement Effect
Ma et al.22 Mice
(129S6/SvEv)
ShamþDMM(m,f),
OVXþDMM,
ORXþDMM,
ORXþDMMþE
6 wk* N¼ 10 6, 10, 12 wk Knee Histologyy e
Oestergaard
et al.18
Rats (SD) Sham, OVX,
OVXþ early E,
OVXþ late E
6 mo N¼ 10/11/
11/10
9 wk Knee Histologyy,
CTX-II
e
Christgau
et al.17
Rats (SD) Sham, OVX, OVXþE,
OVXþSERM_low,
OVXþSERM_high
6 mo N¼ 12 9 wk Knee Histologyy,
CTX-II
e
Hoegh-Andersen
et al.16
Rats (SD) Sham, OVX, OVXþE,
OVXþSERM_low,
OVXþSERM_high
5/7 mo N¼ 10/12 9 wk Knee Histologyy,
CTX-I, CTX-II
e
Dai et al.20 Guinea pigs Sham, OVX 32 mo N¼ 5 0, 6, 12 wk Knee Histology,
SEM, TEM
e
Calvo et al.21 Rabbits (NwZ) Sham, ShamþACLT,
OVX, OVXþACLT
8 mo* N¼ 6 22 wk Knee Histologyy e
Rasanen et al.14 Rabbits (NwZ) Non-operated, OVX,
Shamþ E
21 wk N¼ 5/9/8 22 wk Knee Mech properties,
thickness
e
Claassen et al.15 Miniature pigs
(Gottingen)
Intact, OVX 21 mo N¼ 10 (?) 1 yr Wrist Histology,
immuno
e
Cake et al.13 Sheep (merino) Non-operated, OVX 7 yr N¼ 6 28e30 wk Knee Mech indentation,
histology, immunoy
e
Parker et al.19 Sheep (merino) Non-operated, OVX,
OVXþ LMX,
OVXþ LMXþ E
8e10 yr N¼ 6 3 mo Knee Histologyy e
Turner et al.12 Sheep Sham, OVX, OVXþE,
OVXþ 2E
4e5 yr N¼ 9/13/
10/4
1 yr Knee Mech properties,
thickness
e
Hashem et al.26 Rabbits (NwZ) Sham, OVX, OVXþE,
OVXþP, OVXþR,
OVXþEþR,
OVXþPþR,
OVXþEþPþR
18 wk N¼ 6e8 6 d Knee GAG content,
collagen content
0
Chambers et al.25 Mice (STR/ort) Sham (m,f), OVX, ORX 3e6 wk N¼ 5/6/7 27 wk Knee Histology, immuno 0
Sokoloff et al.23 Mice (DBA) Intact (m,f), ORX,
ORXþE, OVX
5 wk N¼ 23/23/
23/13/19
15 mo Knee Gross
examination
0
Silberberg et al.24 Mice (C57Bl) Sham, OVX (1 m, 6 m) 1, 6 mo N¼ 32/45/64 17, 12 mo Knee Histology 0
Silberberg et al.27 Mice (C57Bl) Intact, OVX (6 m, 12 m) 6, 12 mo N¼ 42/64/53 6, 12 mo Knee Histology þ/0
Note: in the table, all treatments used in a study are mentioned for completeness. However, in the discussion of the OVX effect, only OVX
and control groups were included.
*OVX and OA induction not at same time point. Age is at time of OVX.
yBlinded assessment reported; ACLT¼ anterior cruciate ligament transection; d¼ days; DMM¼ destabilization of medial meniscus;
E¼ estrogen treatment, see Table II for details; f¼ female; immuno¼ immunohistochemistry; LMX¼ lateral meniscectomy; m¼male;
mech¼mechanical; mo¼months; NwZ¼New Zealand; ORX¼ orchiectomy; P¼ progesterone treatment; R¼ relaxin treatment;
SD¼Sprague Dawley; SEM¼ scanning electron microscopy; SERM¼ selective estrogen receptor modulator, see Table III for details;
TEM¼ transmission electron microscopy; wk¼weeks; yr¼ years; þ¼ beneﬁcial effect (lower incidence or severity of osteoarthritic changes);
0¼ no effect; e¼ detrimental effect (higher incidence or severity of osteoarthritic changes); ?¼ not or not clearly described.
535Osteoarthritis and Cartilage Vol. 16, No. 5different in cartilage from estrogen treated and control cyn-
omolgus monkeys33. In male castrated mice, estrogen
treatment did not change the severity of spontaneous
OA23. Also after surgically induced joint instability, estrogen
treatment did not alter the OA severity in male castrated
mice22.
Detrimental effect. In contrast to the beneﬁcial effects of
estrogens, six studies have reported a detrimental effect
of estrogens. An increase in degeneration and cell death
after estradiol treatment in mice was reported34. Estrogen
administration after OVX worsened the surgically induced
cartilage damage in a rabbit model35. Also without surgically
induced OA, Tsai and Liu36 reported a similar effect. In their
study, OVX together with a high dose of intra-articular estra-
diol administration caused degenerative changes. In a laterstudy, Tsai and Liu37 showed that a low dose of estradiol
did not induce pathological changes, whereas a high dose
again caused degenerative changes that progressed over
time. In another rabbit model the proteoglycan synthesis
was decreased in both non-operated normal knees and in
postmeniscectomy osteoarthritic knees of estrogen treated
animals38. A combination of hormones was used in a rabbit
model. Treatment with estradiol, progesterone or relaxin
alone, or in any combination led to a loss of cartilage colla-
gen26. Estradiol alone or estradiol with relaxin showed the
strongest loss of collagen.
Unclear effect. In two studies by Silberberg et al.39,40,
changes in ultrastructure of chondrocytes (organellar devel-
opment) and ﬁbrillarity of the matrix are described in very
young (newborn) mice. However, one can only speculate
Table II
Description of the studies for estrogen effect
Study Animal (strain) Treatment Estrogen Administration Dosage Frequency Age Number Follow-up Joint Measurement Effect
Silberberg
et al.30
Mice
(C57Bl)
Intact (f), intactþ E
(early, middle, late)
Alpha
estradiol
benzoate
Subcut 30 mg Once/wk 1, 6, 12 mo N¼ 26/18/
20/21
19, 14, 8 mo Knee Histology þ
Silberberg
et al.29
Mice
(C57Bl)
Intact (m), ORX,
ORXþ E
Alpha
estradiol
benzoate
Subcut 33 mg Once/wk 3 wk N¼ 30/23/
50
21 mo Knee Histology þ
Silberberg
et al.28
Mice
(C57Bl)
Intact (m), intact
(m)þE (early,
middle, late)
Estradiol
benzoate
Subcut 30 mg Once/wk 1, 6, 12 mo N¼ 57/22/
35/38
19, 14, 8 mo Knee Histology þ
Oestergaard
et al.18
Rats (SD) Sham, OVX, OVXþ
early E, OVXþ
late E
17beta
estradiol
Pellet
subcut
0.25 mg/9 wk Continuously 6 mo N¼ 10/11 9 wk Knee Histologyy,
CTX-II
þ
Christgau
et al.17
Rats (SD) Sham, OVX, OVXþE,
OVXþ SERM_low,
OVXþ SERM_high
17Alpha
ethinyl
estradiol
Oral 0.1 mg/kg 5 d/wk 6 mo N¼ 12 9 wk Knee Histologyy,
CTX-II
þ
Hoegh-
Andersen
et al.16
Rats (SD) Sham, OVX, OVXþE,
OVXþ SERM_low,
OVXþ SERM_high
17alpha
ethinyl
estradiol
Oral 0.1 mg/kg 5 d/wk 5/7 mo N¼ 10/12 9 wk Knee Histologyy,
CTX-I, CTX-II
þ
Rasanen
et al.14
Rabbits
(NwZ)
Non-operated, OVX,
Shamþ E
17beta
estradiol
Oral 4 mg/d Daily 21 wk N¼ 5/9/8 22 wk Knee Mech
properties,
thickness
þ
Parker et al.19 Sheep
(merino)
Non-operated, OVX,
OVXþ LMX,
OVXþ LMXþE
17beta
estradiol
Skin patch 50 mg/d Continuously 8e10 yr N¼ 6 3 mo Knee Histologyy þ
Turner et al.12 Sheep Sham, OVX, OVXþE,
OVXþ 2E
Pure
crystalline
estradiol
Implants 1.5 or 3 pg/d Continuously 4e5 yr N¼ 9/13/
10/4
1 yr Knee Mech
properties,
thickness
þ
Ham et al.31 Cynomolgus
monkeys
OVX, OVXþE Conjugated
equine
estrogens
Oral w0.625 mg/d Daily 7e13 yr N¼ 60 3 yr Knee Histologyy þ
Richmond
et al.32
Cynomolgus
monkeys
OVX, OVXþE Conjugated
equine
estrogen
Oral w0.625 mg/d Daily Adult N¼ ? 2 yr Knee Biochemistry
(SO4 incorp)
þ
Ma et al.22 Mice
(129S6/
SvEv)
ShamþDMM (m,f),
OVXþDMM,
ORXþDMM,
ORXþDMMþE
Estradiol Pellet subcut 0.72 mg/60 d Continuously 6 wk* N¼ 10 2, 4, 8 wk Knee Histologyy 0
Sokoloff
et al.23
Mice (DBA) Intact (m,f),
ORX, ORXþ E,
OVX
Diethylstilbesterol Pellet subcut 1 mg/9 mo Continuously 5 wk N¼ 23/23/
23/13/19
15 mo Knee Gross
examination
0
Ham et al.33 Cynomolgus
monkeys
OVX, OVXþE Conjugated
equine
estrogens
Oral w0.625 mg/d Daily 8e11 yr N¼ 30 3 yr Knee Biochemistry,
immuno
0
Silberberg
et al.34
Mice
(C57Bl)
Sham (m), Shamþ E Alpha estradiol
benzoate
Subcut 120 mg Twice/wk 6 mo N¼ 4 1 d, 1, 2 wk Femoral
head
Histology e
Hashem
et al.26
Rabbits
(NwZ)
Sham, OVX, OVXþE,
OVXþ P, OVXþR,
OVXþ EþR,
OVXþ PþR,
OVXþ Eþ PþR
Beta estradiol Intra-muscular 20 ng/kg Once (?) 18 wk N¼ 6e8 6 d Knee GAG content,
collagen
content
e
Tsai et al.37 Rabbits
(NwZ)
OVX, OVXþElow,
OVXþ Ehigh
Estradiol
benzoate
Intra-articular 0.06, 0.3
mg/kg
Once/3 d ? N¼ 4/8/8 9/12 wk Knee Histology e
Tsai et al.36 Rabbits
(NwZ)
OVX, OVXþE,
OVXþ SERM,
OVXþ Eþ SERM
Estradiol
benzoate
Intra-articular 1 mg/kg Twice/wk Adult N¼ 3 3 wk Knee Histology e
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Rosner et al.35 Rabbits (NwZ) OVXþMMX,
OVXþMMXþ E,
OVXþMMXþ SERM
Estradiol
valerate
Intra-muscular 0.175 mg/kg 3 d/wk ? N¼ 17 12 wk Knee Histologyy,
biochemistry
e
Rosner et al.38 Rabbits (NwZ) MMX (f),
MMXþ Elow,
MMXþ Ehigh
Estradiol
valerate
Intra-muscular 0.4, 1.6 mg/kg Once/2 wk ? N¼ 16/16/18 12 wk Knee Histology,
biochemistry
e
Silberberg
et al.40
Mice (C57Bl) Intact (m), intactþ E Alpha
estradiol
benzoate
? 8 mg Once/wk Newborn N¼ 22 3 d; 1, 2,
4 wk
Femoral
head
Electron
microscopy
?
Silberberg
et al.39
Mice (C57Bl) Intact (m), intactþ E Alpha
estradiol
benzoate
Subcut 60 mg Once 4 wk N¼ 2 2, 4, 8,
24 h; 2,
3, 7 d
Femoral
head
Electron
microscopy
?
*OVX and OA induction not at same time point. Age is at time of OVX.
yBlinded assessment reported; d¼ days; DMM¼ destabilization of medial meniscus; E¼ estrogen treatment; f¼ female; h¼ hours; immuno¼ immunohistochemistry; LMX¼ lateral menis-
cectomy; m¼male; mech¼mechanical; MMX¼medial meniscectomy; mo¼months; NwZ¼New Zealand; ORX¼ orchiectomy; P¼ progesterone treatment; R¼ relaxin treatment;
SD¼Sprague Dawley; SERM¼ selective estrogen receptor modulator, see Table III for details; subcut¼ subcutaneous; wk¼weeks; yr¼ years; w¼ equivalent to dose for women of.;
þ¼ beneﬁcial effect (lower incidence or severity of osteoarthritic changes); 0¼ no effect; e¼ detrimental effect (higher incidence or severity of osteoarthritic changes); ?¼ not or not clearly
described, or unclear effect.
Table III
Description of the studies for SERM effect
Study Animal (strain) Treatment SERM Administration Dosage Frequency Age Number Follow-up Joint Measurement Effect
Christgau
et al.17
Rats (SD) Sham, OVX,
OVXþE,
OVXþSERM_low,
OVXþSERM_high
Levormeloxifene Oral 0.2 or 5 mg/kg 5 d/wk 6 mo N¼ 12 9 wk Knee Histology*,
CTX-II
þ
Hoegh-
Andersen
et al.16
Rats (SD) Sham, OVX,
OVXþE,
OVXþSERM_low,
OVXþSERM_high
# Oral 0.2 or 5 mg/kg 5 d/wk 5 mo N¼ 10/12 9 wk Knee Histology*,
CTX-I, CTX-II
þ
Tsai et al.36 Rabbits
(NwZ)
OVX, OVXþE,
OVXþSERM,
OVXþEþSERM
Tamoxifen Intra-articular 0.35 mg/kg Twice/wk Adult N¼ 3 3 wk Knee Histology þ
Colombo et al.42 Rabbits
(NwZ)
MMX (m),
MMXþ SERM
Tamoxifen
citrate
Oral 0.5 mg/kg 5 d/wk ? N¼ 8 5 wk Knee Histology* þ
Rosner et al.41 Rabbits
(NwZ)
MMX (f),
MMXþ SERM
Tamoxifen Intra-muscular 0.5 mg/kg Daily Immature N¼ 15/20 12 wk Knee Histology*,
biochemistry
þ
Rosner et al.35 Rabbits
(NwZ)
OVXþMMX,
OVXþMMXþE,
OVXþMMXþSERM
Tamoxifen Intra-muscular 1.17 mg/kg 3 d/wk ? N¼ 17 12 wk Knee Histology*,
biochemistry
þ
#: cis-3,4-7-Hydroxy-3-phenyl-4-(4-(2-pyrrolidinoethoxy)phenyl)chromane.
*Blinded assessment reported; d¼ days; E¼ estrogen treatment, f¼ female; m¼male; MMX¼medial meniscectomy; mo¼months; NwZ¼New Zealand; SD¼Sprague Dawley;
wk¼weeks; þ¼ beneﬁcial effect (lower incidence or severity of osteoarthritic changes); ?¼ not or not clearly described.
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538 Y. H. Sniekers et al.: Effect of OVX and E2 in OA animal modelswhether these early developmental changes have a stimu-
lating or mitigating effect on OA or represent the OA pro-
cess at all at this age.
SERM
Beneficial effect. SERMs are a class of medication that act
on the estrogen receptors. Their action can be either agonis-
tic or antagonistic, depending on the tissue. In six out of six
studies administering an SERM, a beneﬁcial effect was
found. The SERMs levormeloxifen and cis-3,4-7-hydroxy-
3-phenyl-4-(4-(2-pyrrolidinoethoxy)phenyl)chromane inhibited
the OVX-induced changes in CTX-II excretion and cartilage
erosion in rats16,17. The SERM tamoxifen was administered
in four of the included studies. Tamoxifen had no effect in
OVX rabbits, but OVX animals that received estradiol and
tamoxifen had less cartilage damage than OVX animals
receiving estradiol alone, suggesting that tamoxifen could
counteract or inhibit the degenerative changes induced by
estradiol36. Tamoxifen decreased the cartilage damage in
a rabbit model with OVX and medial meniscectomy
(MMX)35. Also without OVX, tamoxifen decreased the
cartilage damage in this rabbit model41. Colombo et al.42
found that tamoxifen also offered protection in intact male
rabbits. They hypothesized that the therapeutic effect of
tamoxifen is not related to its anti-estrogenic properties,
since its effect is similar in ovariectomized female35 and
intact male rabbits.Discussion
In this review, we aimed to elucidate the effect of OVX
and estrogen treatment on cartilage in animal models. In
11 animal models, OVX caused biomechanical, composi-
tional or histological changes of the articular cartilage.
Four studies reported no effect of OVX, and only one study
observed less OA after OVX. This means that the evidence
is inconclusive.EXPLORING DIVERSITY IN RESULTSA possible explanation for the inconclusive effects is that
there is a lot of variation in experimental set-up, such as an-
imal species, duration of experiment, and age of the ani-
mals (Table I). Especially the use of sexually immature
animals (e.g., mice younger than 5 weeks of age) may dis-
tort the effect of OVX or estrogen treatment. It is striking that
immature animals were used in ﬁve of the studies that
showed no OVX effect, whereas all animals were mature
in the 11 studies that showed a detrimental effect. When
we would exclude the data obtained with immature animals,
11 out of 14 studies showed a detrimental effect of OVX on
cartilage, which makes the evidence considerably stronger.
Therefore we would advice to use only mature animals in
further experiments on the effect of OVX on OA.
The effect of estrogen treatment on OA was inconclusive,
with 11 out of 22 studies reporting a beneﬁcial effect and six
studies even showing a detrimental effect. In contrast, the
effect of estrogen-like substances or SERMs on OA is
very consistent. Six out of six studies reported a beneﬁcial
effect on OA. In the estrogen treatment studies, there
were again differences in experimental set-up. Apart from
the variation in animal species, duration of experiment,
age of the animals (as mentioned above), the estrogen
treatment studies also showed variation in the type ofestrogen, dosage, and way of administration, which could
affect the circulating levels. Unfortunately, most studies
did not report circulating levels, which makes the compari-
son of the studies more difﬁcult.
The difference between inconclusive effect for estrogen
and a clear beneﬁcial effect for SERMs may be caused
by the different mechanisms or pathways via which SERMs
act. In addition, the variation in experimental set-up is less
in the SERM studies. For instance, in the SERM studies
two different animal species were used (only rats and rab-
bits), whereas in the estrogen studies mice, rats, rabbits,
sheep, and monkeys were used. Furthermore, one could
speculate about a publication bias due to industry involve-
ment in SERM supply. This would also explain the low num-
ber of SERM studies (six studies) compared to estrogen
studies (18 studies). Although this may appear mainly in in-
dustry-related studies, we cannot exclude that there may
also be a publication bias in non-commercial studies.
Another type of bias may be introduced when subjective
outcome measurements such as scoring cartilage damage
on histology were not performed blinded. When only includ-
ing studies with reported blinded assessment of histology or
with objective outcome measurements, there would be nine
studies in which OVX caused detrimental articular cartilage
changes, and only one study reporting no effect. Thus in-
stead of being inconclusive, there would be strong evidence
for a detrimental effect by OVX.POSSIBLE WORKING MECHANISM OF ESTROGENThe molecular mechanism by which estrogen could act
on chondrocytes cannot be extracted easily from the macro-
scopic parameters studied in most animal models. In vitro
experiments could give additional insight in these mecha-
nisms. For instance, estrogens have been found to increase
proteoglycan synthesis43, and decrease matrix metallopro-
teinase-1 (MMP-1) mRNA levels44 and nitric oxide produc-
tion by chondrocytes45. However, other studies have
reported a decrease in collagen and proteoglycan synthe-
sis46,47. The effect of estrogen on chondrocytes seems to
be strongly dependent on the concentration that was used
and further studies are needed to elucidate the molecular
mechanisms.
OVX does not only change estrogen levels, but also pro-
gesterone (down), follicle-stimulating hormone (up), luteiniz-
ing hormone (up), and testosterone (down). Besides, OVX
is often accompanied with an increase in fat mass. This
leads to increased levels of adipokines such as leptin.
There is growing interest in the contribution of adipokines
in several diseases and their role in OA is being investi-
gated. For instance, Simopoulou et al.48 reported that leptin
stimulates the expression of MMPs and interleukin-1 (IL-1),
and thus may be important in OA development49. Body
weight and hormone levels were not always mentioned in
the included studies, so we cannot conclude on their contri-
bution. The OVX-related changes in hormones and adipo-
kines may play a role in the osteoarthritic changes
observed after OVX, and may explain why estrogen treat-
ment could not always reduce the OVX-induced changes.
The effect from estrogen on cartilage is probably not the
only mechanism involved in the development of OA, since
other tissues in the joints are also responsive to estrogen.
Bone cells are known to express estrogen receptors6,50,
and estrogen is one of the important regulators of the
balance between bone formation and bone resorption51.
Alteration in the subchondral bone remodelling, and subse-
quently, the bone structure may lead to changes in load
Table IV
Suggested list of quality criteria for animal studies
Criterion Description
Appropriate controls Sham and/or vehicle treatment,
matched in age, sex, and strain
to experimental group. No historic
controls.
Study population
well described
Details on species, strain, substrain,
sex, age, and initial body weight should
be given.
Sample size
appropriate
Large enough to achieve adequate
statistical power.
Treatment well
described
Details on administration of compounds
(dosage, frequency, way of
administration).
Follow-up period
suitable
a. Long enough to expect changes.
b. Details on drop-outs or lost samples
should be given.
Reliable outcome
measurements
Outcome measures validated or
generally accepted.
Blinded outcome
assessment
Especially for subjective
measurements.
539Osteoarthritis and Cartilage Vol. 16, No. 5distribution across the tibial plateaus. This may in turn
cause cartilage damage. Subchondral bone changes
have indeed been reported in several osteoarthritic
models52e55.
Synovial tissue also contains estrogen receptors7,9, and
estrogen may modulate the levels and activity of certain
growth factors and cytokines produced by synovial cells.
These cytokines play an important role in osteophyte forma-
tion56. Indeed, estrogen treatment increased the levels of
components of the insuline-like growth factor (IGF) system
(IGF-1, -2, IGF binding protein-1, -3) in monkey synovial
ﬂuid57. These proteins may originate from local tissues, in-
cluding synovium, cartilage and bone.QUALITY CRITERIA OF ANIMAL STUDIESAlthough the use of ERT in treatment of OA is controver-
sial because of undesirable side effect (e.g., breast tu-
mours), estrogen treatment and OVX in animal studies
can be very useful to elucidate the pathways involved in
OA. However, we found that there is a lot of variation in ex-
perimental set-up and data reporting, which mystiﬁes the
results of this review. There are no generally accepted cri-
teria for the quality of animal studies to be included in
a (systematic) review, like the criteria for clinical studies.
We narrowed our review to studies selected on the in our
opinion most important quality criterion, namely having an
appropriate control group (sham-operated or non-operated
control for OVX effect, vehicle of no administration for es-
trogen effect). However, one can think of more criteria indi-
cating high quality of an animal study. We suggest a list of
criteria (Table IV). Apart from the use of an appropriate
control group, the study population (sex, age, strain and
substrain of the animal) should be well described. As dis-
cussed above, age of the animal may distort the effect.
Also the treatment should be clearly described. For in-
stance in case of the estrogen treatment (or any other com-
pound), it should be clear how the compound was
administered, in which dosage, and at which frequency.
Another issue of the experimental set-up is the sample
size, which should be appropriate to achieve adequatestatistical power. This depends on the type of measure-
ment and the size of the expected effect. Justiﬁcation of
the number of animals used should be given. This could
be done by means of a power calculation. In none of the
included studies such a power calculation was mentioned.
It is also important that the choice for the follow-up period
is soundly based, since it should be long enough to see an
effect. This may depend on the animal species, the treat-
ment, and the research question. In addition, the outcome
measurements should be validated. In case of scoring car-
tilage damage on histology various scoring systems are
being used. Pritzker et al.58 proposed a scoring system
with a wide application for both clinical and experimental
OA assessment. It would increase comparability between
studies if one such scoring system became the standard
method. Some outcome measurements may be quite
subjective (such as histology) whereas others are more ob-
jective (such as collagen content measured by absor-
bance). Especially in case of subjective measurements, it
is important that the observer is blinded to the treatment,
to avoid bias.
Since some of these criteria may be subject of debate, we
did not apply them to our results. However, we did include
information on these matters in Tables IeIII. Applying these
criteria may inﬂuence our results. We have already de-
scribed the effect when taking into account the age at which
OVX was performed or when including only blinded
assessment.
Apart from the criteria needed to evaluate the quality of
a study and to exclude potential bias, additional information
would help to interpret the data. For instance, circulating
hormone levels and body weight may be of inﬂuence (as
discussed above) and therefore interesting to know. This
would facilitate subgroup analysis.
In conclusion, our review on the effects of OVX and estro-
gen treatment on cartilage in animal models showed incon-
clusive effects. However, the only criterion we applied was
that appropriate controls were performed. We observed that
some valuable criteria were not applied or not mentioned in
the studies we evaluated. We now suggest a list of quality
criteria for animal studies. Formulating and applying these
quality criteria will improve the comparability of studies, fa-
cilitate the evaluation and thus be advantageous for reviews
of literature and for animal studies in general.Conﬂict of interest
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